These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 740299)

  • 21. Fosfomycin: Laboratory studies.
    Woodruff HB; Mata JM; Hernández S; Mochales S; Rodríguez A; Stapley EO; Wallick H; Miller AK; Hendlin D
    Chemotherapy; 1977; 23 Suppl 1():1-22. PubMed ID: 583866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro.
    Kobayashi Y; Sumitani Y; Sugita K; Aikawa N
    Int J Antimicrob Agents; 2007 Dec; 30(6):563-4. PubMed ID: 17900870
    [No Abstract]   [Full Text] [Related]  

  • 23. [Sensitivity to fosfomycin of multiresistant serotype 012 Pseudomonas aeruginosa. Multicenter study].
    Dubrous P; Cavallo JD; Buisson Y
    Pathol Biol (Paris); 1997 Jun; 45(6):472-8. PubMed ID: 9309262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microbes: therapeutic targets or therapeutic tools?
    Mukherjee N
    J Indian Med Assoc; 2003 Sep; 101(9):548, 557. PubMed ID: 15168992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the bactericidal activity of the combination of fosfomycin with other antibiotics by 2 different methods (checkboard and bactericidal curves)].
    Gialdroni Grassi G; Ferrara A; Peona V; Colombo ML
    G Ital Chemioter; 1983; 30(2-3):77-84. PubMed ID: 6376256
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical experience with fosfomycin in urinary tract infections (author's transl)].
    Peters HJ; Eicher R
    MMW Munch Med Wochenschr; 1981 May; 123(18):748-50. PubMed ID: 6785627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
    Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
    J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bacterial resistance to antibiotics].
    Martin C; Martin A; Bonneru JJ; Rocca B; Djehizian C
    Ann Anesthesiol Fr; 1981; 22(6):613-22. PubMed ID: 6124191
    [No Abstract]   [Full Text] [Related]  

  • 30. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Mirakhur A; Gallagher MJ; Ledson MJ; Hart CA; Walshaw MJ
    J Cyst Fibros; 2003 Mar; 2(1):19-24. PubMed ID: 15463841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Etest method for fosfomycin susceptibility of ESBL-producing Klebsiella pneumoniae.
    López-Cerero L; de Cueto M; Díaz-Guerrero MA; Morillo C; Pascual A
    J Antimicrob Chemother; 2007 Apr; 59(4):810-2. PubMed ID: 17289760
    [No Abstract]   [Full Text] [Related]  

  • 32. [Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?].
    Honderlick P; Cahen P; Gravisse J; Vignon D
    Pathol Biol (Paris); 2006; 54(8-9):462-6. PubMed ID: 17027182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevalence and dispersion of plasmids conferring fosfomycin resistance in enterobacteria].
    Hardisson C; Villar CJ; Llaneza J; Mendoza MC
    Pathol Biol (Paris); 1984 Sep; 32(7):755-8. PubMed ID: 6387596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fosfomycin in a hematology department].
    Dinelli CA; Montrasio PL; Tansini G
    Minerva Med; 1978 Dec; 69(59):4111-4. PubMed ID: 740308
    [No Abstract]   [Full Text] [Related]  

  • 35. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nephrological experiences in the treatment of urinary infections by fosfomycin].
    Mioli V; Figus S
    Minerva Med; 1978 Dec; 69(59):4093-6. PubMed ID: 740305
    [No Abstract]   [Full Text] [Related]  

  • 37. Better control of antibiotic resistance.
    Guillemot D; Courvalin P;
    Clin Infect Dis; 2001 Aug; 33(4):542-7. PubMed ID: 11462192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fosfomycin in urogenital infections. Experimental assumptions and clinical results].
    Savoia D; Fontana G; Laudi M; Cauda F
    Minerva Med; 1978 Dec; 69(59):4087-91. PubMed ID: 740304
    [No Abstract]   [Full Text] [Related]  

  • 39. Changing resistance of uropathogens to antibiotics.
    Leibovici L; Tarchizky D; Wysenbeek AJ
    Isr J Med Sci; 1985 Jul; 21(7):627-8. PubMed ID: 4044224
    [No Abstract]   [Full Text] [Related]  

  • 40. [Use of cofosfolactamine in localized bacterial infections].
    Scalzini A; Chiodera A; Sueri L
    G Ital Chemioter; 1984; 31(1-2):205-6. PubMed ID: 6468828
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.